Events Partner Content 2nd Integrin-Targeted Drug Development Summit In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharm
News Rare diseases have tenfold higher impact on healthcare costs... A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common "mass market" conditions.
R&D Rare Disease R&D: one step forward, but a long road ahead With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available.
News Orphazyme 'looking at options' after lead drug hits buffers ... Orphazyme's hopes of getting EU approval for its Niemann-Pick disease type C (NPC) therapy arimoclomol after a rejection by the US FDA last year are dwindling fast.
Events Partner Content Real-World Evidence 2022: Rare Diseases and Innovative Thera... RWE Live convenes those involved in RWE, HTA and more.
Events Partner Content 2nd Mitochondria-Targeted Drug Development Summit Therapies for mitochondrial dysfunction
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
